ProfoundBio Initiates Phase 1/2 Trial for PTK7-Targeted ADC PRO1107

ProfoundBio, a biotech firm specializing in innovative antibody-drug conjugates (ADCs) for cancer treatment, has launched the Phase 1/2 clinical trial for PRO1107, marking a significant step in their mission to enhance patient outcomes. The company's Chief Medical Officer, Dr. Naomi Hunder, expressed optimism about the drug's preclinical data, which suggest that PRO1107 could offer superior safety and efficacy over previous PTK7 ADCs. The drug leverages ProfoundBio's proprietary LD343 platform, featuring a novel hydrophilic linker paired with the clinically proven MMAE payload at a high drug-to-antibody ratio.
The global, open-label, multicenter trial will assess the safety, tolerability, pharmacokinetics, and antitumor effects of PRO1107 on patients with advanced solid tumors such as non-small cell lung, breast, and ovarian cancer. The study is divided into two parts: Part A focuses on determining the optimal dose through a dose-escalation process, while Part B aims to expand treatment to specific tumor types.
Baiteng Zhao, ProfoundBio's CEO, highlighted the company's commitment to delivering groundbreaking ADCs with the potential to be best- or first-in-class treatments for patients in need. The LD343 linker-drug technology was initially presented at the SITC 2023 conference, and the company is eager to bring its benefits to a broad spectrum of patients with PTK7-expressing tumors.
PRO1107 is an ADC that targets the Protein Tyrosine Kinase 7 (PTK7) and is conjugated with ProfoundBio's proprietary hydrophilic MMAE-based linker-drug, LD343. The drug-antibody ratio is maintained at 8, and the MMAE payload is known for its potent microtubule-inhibiting properties, which have been validated in various ADCs. The LD343 platform includes a hydrophilic, cleavable linker that mitigates the hydrophobic nature of the MMAE, allowing for a high drug-antibody ratio and efficient delivery to tumor sites without compromising the ADC's physicochemical and pharmacokinetic properties.
ProfoundBio, headquartered in Seattle, is dedicated to developing novel antibody-based therapeutics for cancer patients. The company's pipeline includes several ADC drug candidates aimed at solid tumors and hematological malignancies, such as rinatabart sesutecan (Rina-S; PRO1184) targeting folate receptor-alpha, PRO1160 targeting CD70, PRO1107 targeting PTK7, and PRO1286, a bispecific ADC targeting two widely expressed solid tumor antigens.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!